The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ECCO 2017 | Identifying which patients should receive which therapy for lung cancer

Name: Identifying which patients should receive which therapy for lung cancer
Uploaded: 2017-01-28T00:00:00.000Z
Duration: 57 s
Description: Keith Kerr, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, Scotland gives an overview of his talk on histological and molecular profiling challenges in lung cancer held at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Dr Kerr explains the importance of identifying which patients should receive which therapy.

Keith Kerr • 28 Jan 2017

ECCO 2017

Lung Cancer

Keith Kerr, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, Scotland gives an overview of his talk on histological and molecular profiling challenges in lung cancer held at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Dr Kerr explains the importance of identifying which patients should receive which therapy.